Trial Profile
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Midazolam (Primary)
- Indications Generalised epilepsy; Partial epilepsies; Seizures
- Focus Adverse reactions
- Acronyms ARTEMIS 2
- Sponsors Proximagen; UCB; UCB Biopharma; Upsher-Smith
- 31 Oct 2023 According to an UCB media release, a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM published in Epilepsy & Behavior journal.
- 31 Oct 2023 Results of a post hoc analysis from this study of NAYZILAM presented in an UCB media release.
- 01 Jan 2023 Results assessing treatment satisfaction, level of anxiety, confidence about traveling with midazolam nasal spray (MDZ-NS), and health-related quality of life in patients with seizure clusters and their caregivers after repeated, intermittent use of MDZ-NS in the outpatient setting published in the Epilepsy and Behavior